EONS11 – ‘A fantastic opportunity“

We are very excited to announce that the EONS11 conference and annual meetings will this year be held at ESMO 2018, from 19-23 October, in Munich, Germany. The EONS Advisory and General Meetings will take place on the morning of 19 October before the ESMO conference starts. As a member of EONS, you will be able to hear about the work our organisation has been doing on your behalf over the last year and learn about our plans for the future. You will also be able to use your vote and participate in our decision-making process. Our own cancer nursing track will run from the 20th to 22nd October.

Registration is now open!

Take advantage of the special cancer nurse registration rate of 404,60 Euros and book now as places will go fast!

Joining our conference with ESMO 2018 (19-23 October) means many extra benefits for EONS members. In addition to EONS11 (cancer nursing track) you will have access to all ESMO sessions, posters, submitted abstracts and teaching sessions. We are also organising a number of satellite symposia with sponsors in order to bring you even more educational opportunities than ever! These partnerships and connections to the medical oncologists will lend a stronger emphasis to our discussions around cancer nursing leadership and the need for increasingly close collaboration with medical oncologists in the multi-disciplinary team.

The EONS11 three-day nursing track will focuses on five major themes:

  • cancer nursing leadership
  • symptom management
  • patient safety
  • new cancer research
  • cancer nurse roles

The call for abstracts is now closed.

Our Scientific Committee of experts is currently working hard on developing a fantastic programme of high-profile speakers on topics related to our five themes. You will hear the latest developments in oncology nursing practice and research from which to learn and develop your own knowledge and skills.

The draft programme is available in the Further Information section on this page. This will be updated as full speaker information is confirmed.

There will also be an EONS Lounge area where members will be able to relax, network with colleagues from all over Europe and talk to the EONS team about all the exciting things that are going on. We will also announce a number of awards, including the highly prestigious EONS Lifetime Achievement Award.

EONS President Lena Sharp
Lena Sharp

EONS President Lena Sharp said: “If there’s one thing you do this year to boost your professional and personal development, EONS11 is it! Our conference will be a fantastic opportunity for deep learning and cultural exchange. The topics we are focusing on in Munich in October go right to the heart of what cancer nursing is about today – the challenges, the opportunities, our aspirations and our goals.

“As well as our three-day cancer nursing track, joining with the congress of our medical oncologist colleagues (ESMO) brings great added value. Not only will EONS nurses have access to all ESMO sessions, but we will be able to build closer links to strengthen that all-important multi-professional team working. This must be a two-way street, and we can all learn from each other on our mutual journey to ensure our patients and their loved ones have the best experience possible during the cancer trajectory. Do join us – make sure you book your place now. EONS11 will be a life-changing and career-enhancing experience!”

Satellite Symposia at EONS11

These events will cover a variety of important cancer nursing topics and feature a range of expert speakers. They will be a great opportunity for learning and knowledge sharing. (The symposia are marked in blue on the EONS11 programme which you can download from the Further Information column on this page.)

Lunch and evening refreshments will be provided for participants at these sessions.

We would like to thank the following companies for their support of nursing education:

Logos of Amgen Oncology, Baxter, Bayer, Bristol-Myers Squibb, Equashield, Helsinn, Johnson &Johnson, Medicines for Europe, Merck, Paxxo, Pfizer Oncology, Roche and Tevadapter